Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C12-iE-DAP is a synthetic, cell-permeable acylated derivative of the peptidoglycan dipeptide iE-DAP (gamma-D-Glu-mDAP). It acts as a potent and specific agonist for the Nucleotide-binding Oligomerization Domain-containing protein 1 (NOD1), an intracellular pattern recognition receptor. By mimicking bacterial motifs, C12-iE-DAP triggers the NOD1 signaling pathway, leading to the activation of NF-κB and MAPK pathways, and the production of inflammatory cytokines. In the context of immune thrombocytopenia (ITP) during pregnancy, it has been investigated for its ability to ameliorate bone marrow mesenchymal stem cell (BM-MSC) injury and promote platelet production via the IFN-I/STAT1 signaling cascade. The molecule incorporates a lauroyl (C12) fatty acid chain to enhance membrane permeability compared to the parent dipeptide.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on C12-iE-DAP.